What is Merck & Co.'s keytruda qlex — intangible assets?

Merck & Co. (MRK) reported keytruda qlex — intangible assets of $886.00M in Q4 2025.

What does keytruda qlex — intangible assets mean?

The total value of intellectual property and intangible assets associated with this specific product.

Discontinued — last reported Q4 '25

Products & Services · Intangible assets

Keytruda Qlex — Intangible assets

Analysis

StatementSegment

CategoryMarket Position

SignalHigher is better

VolatilityStable

First reportedQ4 2025

Last reportedQ4 2025

Rolls up toIntangible assets — net

How to read this metric

An increase indicates investment in the product's long-term competitive advantage, while a decrease may indicate asset impairment or the natural expiration of patent protection.

Detailed definition

This represents the total gross or net value of all intangible assets directly attributable to a specific product line,...

Peer comparison

A core metric for pharmaceutical companies to track the value of their proprietary drug portfolio.

Metric ID: mrk_segment_keytruda_qlex_intangible_assets

Historical Data

1 periods

	Q4 '25
Value	$886.00M

Similar Metrics at Other Companies

AmgenAMGN View metric

Johnson & JohnsonJNJ View metric

AbbVieABBV View metric

Frequently Asked Questions

What is Merck & Co.'s keytruda qlex — intangible assets?: Merck & Co. (MRK) reported keytruda qlex — intangible assets of $886.00M in Q4 2025.
What does keytruda qlex — intangible assets mean?: The total value of intellectual property and intangible assets associated with this specific product.